Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Calithera Biosciences Inc. | Mivavotinib (CB-659) | Non-Hodgkin's lymphoma | Phase 2 | Oral | Oncology | |
| Calithera Biosciences Inc. | Sapanisertib (CB-228) | NRF2-mutated squamous small cell lung cancer (NSCLC) | Phase 2 | Oral | Oncology | |
| Calithera Biosciences Inc. | Telaglenastat (CB-839) and Vidaza (azacitidine) | Myelodysplastic Syndrome | Phase 2 | Telaglenastat oral Vidaza subcutaneous or intravenous | Hematology | |
| Calliditas Therapeutics AB | Setanaxib - (TRANSFORM) | Primary biliary cholangitis (PBC) | Phase 2b | Data Released | Oral | Gastroenterology |
| Calliditas Therapeutics AB | Setanaxib with pembrolizumab | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Phase 2 | Data Released | Intravenous | Oncology |
| Calliditas Therapeutics AB | Setanaxib | Alport Syndrome | Phase 2 | Enrollment Initiation | Oral | Genetic Disorder |
| Calliditas Therapeutics AB | Nefecon (VR-205) | IgA nephropathy (IgAN) | Phase 3 | Enrollment Initiation | Oral | Immunology |
| Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) | Piclidenoson (CF101) | Glaucoma | Phase 2 | Trial Discontinued | Oral | Opthalmic |
